Evaluate Cancer Therapy Response in Real-Time for Better Patient Outcomes
The Veridapt DX™ predictive biomarker platform measures tumor response to cancer drugs to guide oncology treatment decisions.
Every day counts in the fight against cancer
Cancer treatment has come a long way. But we can do better:
Assess the effect of neoadjuvant therapy as early as 5 weeks into treatment.
Escalate or de-escalate therapy based on early tumor response.
Reduce toxic effects and cost of therapies that don’t work as expected.
A PREDICTIVE BIOMARKER PLATFORM
Actionable insights to optimize early treatment strategies
The Veridapt DX™ predictive biomarker measures early tumor response to neoadjuvant treatment to predict the likelihood of disease-free survival.
The test identifies non-responsive solid tumors by monitoring the degree of RNA (rRNA) disruption in the cells.
This enables physicians to escalate or de-escalate therapy, or select an alternative strategy, as early as five weeks into a standard 6-month treatment regimen.
Physicians
Actionable insight into molecular and pathological changes in a tumor during initial treatment.
Patients
Earlier access to efficacious treatment for better outcomes with fewer toxic side effects.
Payers
Cost savings and a more responsive, efficient and effective healthcare system.
VALIDATION:
BREVITY Clinical Trial
Phase 1 results demonstrated Veridapt DX’s strong capability to accurately predict therapy efficacy/outcomes during early treatment (Negative Predictive Value >93%).
Phase 2 is now under way in 7 countries.
Learn more about the BREVITY trial.
ABOUT US
Innovation in personalized medicine for cancer therapy management
Rna Diagnostics is a clinical stage molecular diagnostics company leading a paradigm shift in early-stage cancer care.
Our Veridapt DX predictive biomarker platform delivers timely, actionable insight into primary cancer treatment efficacy for solid tumors.
Our initial focus is on primary breast cancer; however, our assay platform is applicable to any solid tumor and any cancer drug therapy for personalized, precision medicine.